Ireland· IE-PA-PA23005/001/001
Metopirone 250 mg soft capsules
A metyrapone product containing metyrapone, registered in Ireland by Esteve Pharmaceuticals S.A.. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Metyrapone is registered in 14 of 19 countries.
Countries holding a registration under ATC V04CD01 (metyrapone), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Metyrapone · ATC V04CD01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of metyrapone costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Metyrapone · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$91.87
- FR France$70.58
The record
At a glance
HPRA (Ireland)- Active substance
- Metyrapone
- Manufacturer
- Esteve Pharmaceuticals S.A.
- Country
- Ireland (IE)
- ATC code
- V04CD01
- ATC class
- Metyrapone
- Defined daily dose
- 3 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA23005/001/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
14 interactions on record for metyrapone.
Graded by severity as the source publishes them — 14 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metyrapone · interactions on record
14 records
- 14 moderate
Most severe, free to view
- CyproheptadinA15AA01moderate
- EstradiolD11AX34moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Desogestrel and ethinylestradiolG03AA09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Metyrapone in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMETOPIRONEEsteve Pharmaceuticals S.A., Barcelona
- SpainMETOPIRONE 250 MG CAPSULAS BLANDASEsteve Pharmaceuticals S.A.
- FinlandMetopironeEsteve Pharmaceuticals S.A.S.
- FranceMETYRAPONE ESTEVE 250 mg, capsule molleESTEVE PHARMACEUTICALS (ESPAGNE)
- NorwayMetycorEsteve Pharmaceuticals S.A
- PolandMetopironeEsteve Pharmaceuticals, S.A.
- BelgiumMetycor 250 mgHRA Pharma France
- SwedenMetopirone 250 mg Kapsel, mjukEsteve Pharmaceuticals S.A.
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Metycor
- Bulgaria · Metopirone
- Czechia · Metopirone
- Germany · Metopiron
- Denmark · Metopirone
- Estonia · Cormeto
- Spain · Metopirone
- Finland · Metopirone
- France · Metyrapone Esteve
- Greece · Metopirone
- Croatia · Metopirone
- Hungary · Cormeto
- Italy · Cormeto
- Lithuania · Cormeto
- Latvia · Metopirone
- Netherlands · Metopirone
- Norway · Metycor
- Poland · Metopirone
- Portugal · Metopirone Esteve Pharmaceuticals
- Romania · Metopirone
- Sweden · Metopirone
- Slovenia · Metycor
- Slovakia · Metopirone
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8076b7dd-c2bf-4a65-8983-3fab9c93300d GET /v1/drugs/8076b7dd-c2bf-4a65-8983-3fab9c93300d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, soft",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"V04CD",
"V04CD01"
],
"strength": null,
"pa_number": "PA23005/001/001",
"substances": [
"Metyrapone"
],
"legal_basis": "Well-established use application (Article 10a of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "03/02/2012",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about metyrapone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.